Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nous-209 and Pembrolizumab in dMMR/MSI-H Solid Tumors
NCT04041310Phase 2Active, not recruiting
- Sponsor
- Nouscom
- Start
- Oct 2019
- Primary completion
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
A Phase 2 trial of NOUS-209 in colorectal cancer (CRC), gastric cancer (GC), gastroesophageal junction cancer, sponsored by Nouscom. Started Oct 2019; status: active, not recruiting.
02
Drugs
NOUS-209
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04041310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04041310.